Could This Be The Biggest Stock Of 2023?
This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!
Continue Reading
pixel

DEST Insider Trading

Insider Ownership Percentage: 24.31%
Insider Buying (Last 12 Months): £6,800
Insider Selling (Last 12 Months): GBX 0

Destiny Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at Destiny Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Destiny Pharma Share Price & Price History

Current Price: GBX 30.40
Price Change: Price Decrease of -1.1 (-3.49%)
As of 03/22/2023 10:40 PM ET

This chart shows the closing price history over time for DEST up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Destiny Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/27/2023Nick RodgersInsiderBuy20,000GBX 34£6,800
9/27/2021Nick RodgersInsiderBuy2,100£119.80£251,580
4/29/2021Nick RodgersInsiderBuy1,511GBX 149£2,251.39
4/22/2021Nick RodgersInsiderBuy5,000GBX 158£7,900
1/6/2021Nick RodgersInsiderBuy9,000GBX 88£7,920
See Full Table
The Stock That Is Flying Under Wall St. Radar
With The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!
Continue Reading
pixel

SEC Filings (Institutional Ownership Changes) for Destiny Pharma (LON:DEST)

19.08% of Destiny Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Destiny Pharma logo
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
Read More on Destiny Pharma

Today's Range

Now: GBX 30.40
Low: 30.40
High: 32

50 Day Range

MA: GBX 47.31
Low: 30.40
High: 60.90

52 Week Range

Now: GBX 30.40
Low: 29.20
High: 61.85

Volume

34,742 shs

Average Volume

372,420 shs

Market Capitalization

£26.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.38

Who are the company insiders with the largest holdings of Destiny Pharma?

Destiny Pharma's top insider investors include:
  1. Nick Rodgers (Insider)
Learn More about top insider investors at Destiny Pharma.
Could This Be The Biggest Stock Of 2023?
This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!
Continue Reading
pixel